A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [6]
In the citing paper
“Application of the BCS in waiving BA/BE requirements is based on premises that if (1) two immediate-release (IR) drug formulations/products behave as oral solutions within the GI tract due to high solubility and rapid dissolution, (ii) no precipitation occurs in the GI tract once the API is dissolved, and (iii) the two IR formulations have the same in vivo dissolution profile under all intestinal”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
Citations
Cites
Diffusion, mass transfer in fluid systems
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0927 · Cited by 4,930
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
The effect of particle size distribution on dissolution rate and oral absorption
HINTZ, R., & JOHNSON, K. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90069-0 · Cited by 331
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Self-citationOh, D.-M., Curl, R. L., & Amidon, G. L. (1993) · Pharmaceutical Research · doi:10.1023/a:1018947113238 · Cited by 253
Self-citationRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Self-citationOberle, R. L., & Amidon, G. L. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061761 · Cited by 208
Self-citationRegional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202
Self-citationPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178
Self-citationIn Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants
Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., & Skelly, J. P. (1989) · Pharmaceutical Research · doi:10.1023/a:1015909716312 · Cited by 162
Self-citation
Research works printed but not linked: 5
- E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
- G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
- V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
- H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
- The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
Cited by
Items 901–1,000 of 1,018
Wet milling induced physical and chemical instabilities of naproxen nano-crystalline suspensions
Kumar, S., & Burgess, D. J. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.03.021 · Cited by 72
The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance
Selen, A., Dickinson, P. A., Müllertz, A., Crison, J. R., Mistry, H. B., Cruañes, M. T., Martinez, M. N., Lennernäs, H., Wigal, T. L., Swinney, D. C., et al. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24162 · Cited by 75
Self-citationAqueous solubility: Simple predictive methods (in silico, in vitro and bio-relevant approaches)
Elder, D. P., & Holm, R. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.10.041 · Cited by 72
Bala, I., Bhardwaj, V., Hariharan, S., Sitterberg, J., Bakowsky, U., & Kumar, M. N. V. R. (2005) · Nanotechnology · doi:10.1088/0957-4484/16/12/014 · Cited by 72
Biopharmaceutics classification of puerarin and comparison of perfusion approaches in rats
Li, H., Dong, L., Li, X., Wang, G., Wang, G., & Qiao, Y. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.03.014 · Cited by 74
Kim, B.-G., Choi, S.-Y., Kim, M.-R., Suh, H. J., & Park, H. J. (2010) · Process Biochemistry · doi:10.1016/j.procbio.2010.04.026 · Cited by 72
Rate- and Extent-Limiting Factors of Oral Drug Absorption: Theory and Applications
Sugano, K., & Terada, K. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24391 · Cited by 78
Cheow, W. S., & Hadinoto, K. (2012) · Particuology · doi:10.1016/j.partic.2011.08.007 · Cited by 72
Reddy, L. H., Urmann, M., Besenius, M., Ulrich, W., Haack, T., Brun, P., Alié, J., Illel, B., Hortala, L., Vogel, R., et al. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.011 · Cited by 77
Reformulating cyclosporine A (CsA): More than just a life cycle management strategy
Guada, M., Beloqui, A., Kumar, M. N. V. R., Préat, V., Dios-Viéitez, M. D. C., & Blanco‐Prieto, M. J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.056 · Cited by 78
“Owing to its low solubility and low permeability through the physiological barriers, CsA is classified as Class IV according to the Biopharmaceutics Classification System [23,37].”
BackgroundOral Formulations for Preclinical Studies
Gao, Y., Gesenberg, C., & Zheng, W. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802447-8.00017-0 · Cited by 83
Kunnath, K. T., Huang, Z., Chen, L., Zheng, K., & Davé, R. N. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.04.002 · Cited by 71
Six, K., Murphy, J., Weuts, I., Craig, D. Q. M., Verreck, G., Peeters, J., Brewster, M. E., & den Mooter, G. V. (2003) · Pharmaceutical Research · doi:10.1023/a:1022219429708 · Cited by 71
Fu, J., Lishuang, X., Xiaoli, W., Zhang, S., Tao, X., Zhao, X., He, H., & Xing, T. (2011) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2010.550301 · Cited by 71
“In addition, 40% alcohol was selected as the solvent and the coating temperature was set at 40°C. Hansen solubility parameter calculations The Hansen solubility parameters of the drug and the polymers were calculated from their chemical structures using the Hoftyzer and Krevelen13 method according to Equation (1). δ =…”
BackgroundMethodInfluentialIs the full potential of the biopharmaceutics classification system reached?
Bergström, C. A. S., Andersson, S. B. E., Fagerberg, J. H., Ragnarsson, G., & Lindahl, A. H. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.09.010 · Cited by 71
Dissolution enhancement of drugs. part i: technologies and effect of carriers
Saharan, V. A., Kukkar, V., Kataria, M. K., Gera, M., & Choudhury, P. K. (2010) · International Journal of Health Research · doi:10.4314/ijhr.v2i2.55401 · Cited by 89
Neuhoff, S., Yeo, K. R., Barter, Z. E., Jamei, M., Turner, D. B., & Rostami‐Hodjegan, A. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23594 · Cited by 73
Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach
Dahan, A., Khamis, M. I., Agbaria, R., & Karaman, R. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.697055 · Cited by 71
Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364
Sotthivirat, S., McKelvey, C. A., Moser, J. D., Rege, B. D., Xu, W., & Zhang, D. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.037 · Cited by 71
Mitra, A., Kesisoglou, F., & Dogterom, P. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0194-8 · Cited by 72
Bergström, C. A. S. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960303.x · Cited by 78
High throughput solubility measurement with automated polarized light microscopy analysis
Sugano, K., Kato, T., Suzuki, K., Keiko, K., Sujaku, T., & Mano, T. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20628 · Cited by 71
Metsugi, Y., Miyaji, Y., Ogawara, K., Higaki, K., & Kimura, T. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9469-z · Cited by 72
“Since most drugs are mainly absorbed from the small intestine, but not from the stomach, gastric emptying is the rate-limiting step for drug absorption, particularly for drugs with high permeability and high solubility as classified in BCS class I (25).”
BackgroundFluoroquinolone salts with carboxylic acids
Reddy, J. S., Ganesh, S. V., Nagalapalli, R., Dandela, R., Solomon, K. A., Kumar, K. A., Goud, N. R., & Nangia, A. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22537 · Cited by 71
Nguyen, M. A., Flanagan, T. R., Brewster, M. E., Kesisoglou, F., Beato, S., Biewenga, J., Crison, J. R., Holm, R., Li, R., Mannaert, E., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.02.029 · Cited by 71
“The most prominent approach to identify compounds with dissolution and/or permeation as the rate-limiting step for absorption was launched by Amidon and coworkers as the Biopharmaceutics Classification System (BCS) N20years ago (Amidon et al., 1995).”
BackgroundSelf-citationHagedorn, M., Bögershausen, A., Rischer, M., Schubert, R., & Massing, U. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.047 · Cited by 71
Griffin, B. T., & O’Driscoll, C. M. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.7.0006 · Cited by 71
“Saquinavir is classified as a Class II compound, in accordance with the terms of the Biopharmaceutical Drug Classification Scheme (Amidon et al 1995).”
MethodAbdel‐Rahman, S. M., Amidon, G. L., Kaul, A., Lukáčová, V., Vinks, A. A. T. M. M., & Knipp, G. T. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.014 · Cited by 70
Self-citationTan, S. L. J., & Billa, N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111817 · Cited by 76
The Low/High BCS Permeability Class Boundary: Physicochemical Comparison of Metoprolol and Labetalol
Zur, M., Gasparini, M., Wolk, O., Amidon, G. L., & Dahan, A. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500152y · Cited by 72
Self-citationOchi, M., Kawachi, T., Toita, E., Hashimoto, I., Yuminoki, K., Onoue, S., & Hashimoto, N. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.08.022 · Cited by 70
Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process
Purvis, T., Mattucci, M. E., Crisp, M. T., Johnston, K. P., & Williams, R. O. (2007) · AAPS PharmSciTech · doi:10.1208/pt0803058 · Cited by 70
“BCS class II compounds are poorly soluble but highly permeable, and they exhibit bioavailability that is limited by dissolution rate.(1) The dissolution rate of BCS class II drug substances may be accelerated by improvement of the wetting characteristics of the bulk powder.”
BackgroundKhadra, I., Zhou, Z., Dunn, C., WILSON, C. G., & Halbert, G. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.10.019 · Cited by 70
“The mechanistic concept of the two stage process was first formalised in the biopharmaceutics classification system (BCS), which teaches that drug solubility and gastrointestinal permeability are two key factors controlling oral bioavailability (Amidon et al., 1995).”
BackgroundCao, F., Jia, J., Yin, Z. Q., Gao, Y., Sha, L., Lai, Y., Ping, Q., & Zhang, Y. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200447r · Cited by 70
Dai, W., Pollock‐Dove, C., Dong, L. C., & Li, S. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.017 · Cited by 75
Orrego-Lagarón, N., Martínez‐Huélamo, M., Vallverdú‐Queralt, A., Lamuela-Raventós, R. M., & Escribano‐Ferrer, E. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515001671 · Cited by 70
“As a model drug, and according to the Biopharmaceutics Classification System (BCS)((5)), naproxen was assayed as a high-permeability reference compound; (2) to evaluate the intestinal and hepatic first-pass effect through the detection and quantification of metabolites in the lumen, bile and plasma; (3) to study the i…”
InfluentialGuerra, A., Denis, S., le Goff, O., Sicardi, V., François, O., Yao, A., Garrait, G., Manzi, A. P., Beyssac, E., Alric, M., et al. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25890 · Cited by 70
“…the composition of digestive fluids (such as buffer capacity, osmolality, viscosity, bile salts concentrations) greatly vary from fasted to fed state and can significantly impact drug dissolution and absorption (Amidon et al., 1995; Jantratid et al., 2008; Mudie et al., 2010; Sheng et al., 2009).”
BackgroundRegional Intestinal Permeability of Three Model Drugs in Human
Dahlgren, D., Roos, C., Lundqvist, A. J., Abrahamsson, B., Tannergren, C., Hellström, P. M., Sjögren, E., & Lennernäs, H. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00514 · Cited by 73
Self-citationCellulose and its derivatives for application in 3D printing of pharmaceuticals
Giri, B. R., Poudel, S., & Kim, D. W. (2020) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-020-00498-5 · Cited by 70
Contemporary Formulation Development for Inhaled Pharmaceuticals
Sou, T., & Bergström, C. A. S. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.09.006 · Cited by 75
Unlocking the potential of drug-drug cocrystals – A comprehensive review
Banerjee, M., Nimkar, K. R., Naik, S. V., & Patravale, V. B. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.003 · Cited by 70
Vaithianathan, S., Haidar, S. H., Zhang, X., Jiang, W., Avon, C., Dowling, T. C., Shao, C., Kane, M. A., Hoag, S. W., Flasar, M. H., et al. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24643 · Cited by 69
Hu, L., Sun, H., Zhao, Q., Han, N., Bai, L., Wang, Y., Jiang, T., & Wang, S. (2014) · Materials Science and Engineering C · doi:10.1016/j.msec.2014.10.067 · Cited by 69
Barmpalexis, P., Koutsidis, I. A., Karavas, E., Louka, D., Papadimitriou, S. A., & Bikiaris, D. Ν. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.03.013 · Cited by 69
“To confront this, several technological methods have been reported for the improvement of API solubility and dissolution rate [1–3].”
MethodGershanik, T., Haltner, E., Lehr, C., & Benita, S. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00591-3 · Cited by 69
Sigfridsson, K., Forssén, S., den Hollander, P. H. C., Skantze, U., & de Verdier, J. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.02.008 · Cited by 69
Use of thin film freezing to enable drug delivery: a review
Overhoff, K. A., Johnston, K. P., Tam, J., Engstrom, J. D., & Williams, R. O. (2009) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(09)50016-0 · Cited by 69
Duret, C., Wauthoz, N., Sebti, T., Vanderbist, F., & Amighi, K. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.002 · Cited by 78
A decision-support tool for the formulation of orally active, poorly soluble compounds
Branchu, S., Rogueda, P., Plumb, A. P., & Cook, W. G. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.06.005 · Cited by 69
Nanonization of megestrol acetate by laser fragmentation in aqueous milieu
Sylvestre, J., Tang, M.-C., Fürtös, A., Leclair, G., Meunier, M., & Leroux, J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.034 · Cited by 70
“Incomplete oral bioavailability occurs when the dissolution rate of a drug is so slow, that dissolution takes longer than the transit time past its absorptive sites [3,4].”
BackgroundTuning solubility and stability of hydrochlorothiazide co-crystals
Sanphui, P., & Rajput, L. (2013) · Acta Crystallographica Section B Structural Science Crystal Engineering and Materials · doi:10.1107/s2052520613026917 · Cited by 69
“It is a BCS (Biopharmaceutics Classification System) class IV drug (Amidon et al., 1995) of low solubility (0.7 g L 1 at 298 K) and low permeability (log P = 0.07).”
BackgroundInfluentialRohrschneider, M., Bhagwat, S., Krampe, R., Michler, V., Breitkreutz, J., & Hochhaus, G. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00221 · Cited by 69
Preclinical hazard evaluation strategy for nanomedicines
Siegrist, S., Çörek, E., Detampel, P., Sandström, J., Wick, P., & Huwyler, J. (2018) · Nanotoxicology · doi:10.1080/17435390.2018.1505000 · Cited by 74
“…on the International Organization of Standardization (ISO) definition of the term ‘nanoparticle’ and takes up a similar classification approach as used, for example, in the Biopharmaceutics Classification System (BCS) to estimate the oral bioavailability of drugs (Amidon et al. 1995; ISO 2015).”
MethodPiton, J., Vocat, A., Lupien, A., Foo, C. S.-Y., Riabova, O., Makarov, V., & Cole, S. T. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00681-18 · Cited by 72
“Revisiting the SAR of MCZ further provides the opportunity to improve pharmacodynamics properties of MCZ such as aqueous solubility to increase its oral bioavailability, metabolic stability, and in vivo activity (25).”
BackgroundPosaconazole Cocrystal with Superior Solubility and Dissolution Behavior
Kuminek, G., Cavanagh, K. L., Piedade, M. F. M., & Rodríguez‐Hornedo, N. (2019) · Crystal Growth & Design · doi:10.1021/acs.cgd.9b01026 · Cited by 69
Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factors
Bergman, E., Forsell, P., Persson, E. M., Knutson, L., Dickinson, P. A., Smith, R. P., Swaisland, H., Farmer, M. R., Cantarini, M., & Lennernäs, H. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.002 · Cited by 69
Self-citationBibi, H. A., Holm, R., & Bauer-Brandl, A. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.05.001 · Cited by 68
“Many of the newly developed chemical entities in the pharmaceutical industry have a high permeability, but a poor aqueous solubility, hence being classified as class II drugs in the biopharmaceutical classification system (BCS) [1].”
BackgroundLust, A., Strachan, C. J., Veski, P., Aaltonen, J., Heinämäki, J., Yliruusi, J. K., & Kogermann, K. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.03.079 · Cited by 68
“As PRX has low aqueous solubility and high permeability, it is a Class II drug in the Biopharmaceutics Classification System (Amidon et al., 1995).”
BackgroundTajarobi, F., Larsson, A., Matic, H., & Abrahmsén‐Alami, S. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.11.020 · Cited by 68
In Vitro–In Vivo Correlation of Efavirenz Tablets Using GastroPlus®
Honório, T. D. S., Pinto, E. C., Rocha, H. V. A., Esteves, V. S. D., dos Santos, T. C., Castro, H. C., Rodrigues, C. R., de Sousa, V. P., & Cabral, L. M. (2013) · AAPS PharmSciTech · doi:10.1208/s12249-013-0016-4 · Cited by 68
Persson, E. M., Nilsson, R. G., Hansson, G. I., Löfgren, L., Libäck, F., Knutson, L., Abrahamsson, B., & Lennernäs, H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9607-z · Cited by 68
“The net water flux (NWF, in milliliters per hour per centimeter) in the isolated jejunal segment was calculated according to Eq. ( 1 ):”
MethodSelf-citationMartinez, M., Augsburger, L., Johnston, T., & Jones, W. W. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00070-4 · Cited by 73
Watanabe, E., Takahashi, M., & Hayashi, M. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.029 · Cited by 68
Idkaidek, N., & Arafat, T. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300250r · Cited by 69
Cvijić, S., Parojčić, J., Ibric, S. R., & Djurić, Z. (2010) · AAPS PharmSciTech · doi:10.1208/s12249-010-9573-y · Cited by 68
“1) that relates the extent of drug absorption to its dose number, assuming the drug is highly permeable (9):”
BackgroundEffect of Polymer Molecular Weight on Nanocomminution of Poorly Soluble Drug
Choi, J.-Y., Park, C. H., & Lee, J. (2008) · Drug Delivery · doi:10.1080/10717540802039113 · Cited by 68
“Itraconazole can benefit from particle size reduction since it is a class II drug according to the BCS systems (Six 2004; Amidon et al. 1995).”
MethodCrum, M., Trevaskis, N. L., Williams, H. D., Pouton, C. W., & Porter, C. J. H. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1843-7 · Cited by 70
“Low drug solubility and dissolution in gastrointestinal (GI) fluids is therefore a potential limitation to effective drug absorption as it prevents the attainment of the high drug concentrations required to achieve maximal drug flux across the intestinal wall (1, 2).”
BackgroundInteractions between cyclodextrins and cellular components: Towards greener medical applications?
Leclercq, L. (2016) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.12.261 · Cited by 74
Yuliandra, Y., Zaini, E., Syofyan, S., Pratiwi, W., Putri, L. N., Pratiwi, Y. S., & Arifin, H. (2018) · Scientia Pharmaceutica · doi:10.3390/scipharm86020023 · Cited by 68
“The low solubility of these drugs may cause inconsistency for a complete absorption, despite the fact that they are highly membrane permeable [34].”
BackgroundPalucki, M., Higgins, J. D., Kwong, E. C., & Templeton, A. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1002638 · Cited by 72
Six, K., Leuner, C., Dressman, J., Verreck, G., Peeters, J., Blaton, N. M., Augustijns, P., Kinget, R., & den Mooter, G. V. (2002) · Journal of Thermal Analysis and Calorimetry · doi:10.1023/a:1016056222881 · Cited by 68
Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery
Gobeau, N., Stringer, R., De Buck, S., Tuntland, T., & Faller, B. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1951-z · Cited by 67
Tachibana, T., Kato, M., Watanabe, T., Mitsui, T., & Sugiyama, Y. (2009) · Xenobiotica · doi:10.1080/00498250902846252 · Cited by 67
“The widely used Biopharmaceutical Classification System (BCS) presented by Amidon et al. (1995) categorizes drugs into four classes according to solubility and permeability.”
MethodPezik, E., Gülsün, T., Şahin, S., & Vural, İ. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105597 · Cited by 67
López-Vidal, L., Real, J. P., Real, D. A., Camacho, N. M., Kogan, M. J., Paredes, A. J., & Palma, S. D. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121311 · Cited by 67
Bocci, G., Oprea, T. I., & Benet, L. Z. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00687-0 · Cited by 62
“Major drug regulatory agencies use the BCS (2) to assess the eligibility of drugs for a waiver of in vivo bioequivalence studies (3, 8).”
BackgroundDevelopment of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor
Xue, M., Hu, S. X., Lü, Y., Zhang, Y., Jiang, X., An, S., Guo, Y., Zhou, X., Hou, H., & Jiang, C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.056 · Cited by 69
Lennernäs, H. (2009) · Molecular Pharmaceutics · doi:10.1021/mp9000876 · Cited by 82
Self-citationLozoya-Agulló, I., González‐Álvarez, I., González‐Álvarez, M., Merino‐Sanjuán, M., & Bermejo, M. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24447 · Cited by 72
Coamorphous Atorvastatin Calcium to Improve its Physicochemical and Pharmacokinetic Properties
Shayanfar, A., Ghavimi, H., Hamishekar, H., & Jouyban, A. (2013) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3xs4s · Cited by 68
“According to the BCS, ATC falls into Class II (3), i.e., low solubility and high permeability (4).”
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C
Gentile, I., Maraolo, A. E., Buonomo, A. R., Zappulo, E., & Borgia, G. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1094051 · Cited by 69
“According to the Biopharmaceutics Classification System, SOF is class 3 compound, that is, a high-solubility and low-permeability drug [60].”
MethodDémuth, B., Farkas, A., Pataki, H., Balogh, A., Szabó, B., Borbás, E., Sóti, P. L., Vígh, T., Kiserdei, É., Farkas, B., et al. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.12.029 · Cited by 67
Polymeric microcontainers improve oral bioavailability of furosemide
Nielsen, L. H., Melero, A., Keller, S. S., Jacobsen, J. B., Garrigues, T., Rades, T., Müllertz, A., & Boisen, A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.03.050 · Cited by 80
Dynamic dissolution-/permeation-testing of nano- and microparticle formulations of fenofibrate
Sironi, D., Rosenberg, J., Bauer‐Brandl, A., & Brandl, M. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.09.001 · Cited by 67
Selective Inhibitors of Human Neuraminidase 3
Guo, T., Dätwyler, P., Demina, E. P., Richards, M. R., Ge, P., Zou, C., Zheng, R. B., Fougerat, A., Pshezhetsky, A. V., Ernst, B., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01574 · Cited by 71
Davanço, M. G., de Campos, D. R., & Carvalho, P. D. O. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119210 · Cited by 76
Matsui, K., Tsume, Y., Amidon, G. E., & Amidon, G. L. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00135 · Cited by 67
Self-citationAzad, M. A., Afolabi, A., Bhakay, A., Leonardi, J., Davé, R. N., & Bilgili, E. A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.028 · Cited by 67
Molecular and Pharmacokinetic Properties of 222 Commercially Available Oral Drugs in Humans.
Sakaeda, T., Okamura, N., Nagata, S., Yagami, T., Horinouchi, M., Okumura, K., Yamashita, F., & Hashida, M. (2001) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.24.935 · Cited by 71
Jantratid, E., Prakongpan, S., Dressman, J., Amidon, G. L., Junginger, H. E., Midha, K. K., & Barends, D. M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20614 · Cited by 67
“The minimum solubility determined in the pH range 1–8 at 378C is 6 mg/mL.(18)”
BackgroundResultSelf-citationBabadi, D., Dadashzadeh, S., Osouli, M., Abbasian, Z., Daryabari, M. S., Sadrai, S., & Haeri, A. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102324 · Cited by 72
Impact of nanotechnology on the oral delivery of phyto-bioactive compounds
Nsairat, H., Lafi, Z., Al-Sulaibi, M., Gharaibeh, L. F., & Alshaer, W. (2023) · Food Chemistry · doi:10.1016/j.foodchem.2023.136438 · Cited by 74
Berlin, M., Przyklenk, K.-H., Richtberg, A., Baumann, W., & Dressman, J. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.08.011 · Cited by 68
Schellekens, R. C. A., Stuurman, F. E., van der Weert, F. H. J., Kosterink, J. G. W., & Frijlink, H. W. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.09.004 · Cited by 73
“The Biopharmaceutics Classification System has been proposed to correlate in vitro drug product dissolution and in vivo systemic bioavailability from immediate release formulations [6].”
BackgroundFormation of itraconazole/L-malic acid cocrystals by gas antisolvent cocrystallization
Ober, C. A., Montgomery, S. E., & Gupta, R. B. (2012) · Powder Technology · doi:10.1016/j.powtec.2012.04.058 · Cited by 66
Shayanfar, A., & Jouyban, A. (2013) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-013-9162-1 · Cited by 66
“Class II compounds have low solubility and high permeability and so they exhibit solubility-limited absorption [2].”
BackgroundLópez, J. R. M., Salazar, D. K., Hurtado, M., Cortés, A. R., & Domínguez‐Ramírez, A. M. (2013) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.02.001 · Cited by 66
“The Biopharmaceutics Classification System groups drugs into four classes (Amidon et al., 1995).”
Jones, C. R., Hatley, O. J. D., Ungell, A.-L. B., Hilgendorf, C., Peters, S. A., & Rostami‐Hodjegan, A. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9889-y · Cited by 72
Crystal Engineering of Isostructural Quaternary Multicomponent Crystal Forms of Olanzapine
Clarke, H. D., Hickey, M. B., Moulton, B., Perman, J. A., Peterson, M. L., Wojtas, Ł., Almarsson, Ö., & Zaworotko, M. J. (2012) · Crystal Growth & Design · doi:10.1021/cg3007052 · Cited by 66
Preparation and characterization of furosemide nanosuspensions
Gülsün, T., Borna, S. E., Vural, İ., & Şahin, S. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.03.005 · Cited by 66
Metadata
- Authors
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R.
- Affiliations
- University of Michigan (US)
- Uppsala University (SE)
- United States Food and Drug Administration (US)
- Therapeutics Systems Research Laboratories (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 1995-03
- Volume
- 12
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1498305210
- Cited by
- 5,430
- References
- 29
- Citations by year
- 2026: 170 · 2025: 201 · 2024: 182 · 2023: 240 · 2022: 266 · 2021: 282 · 2020: 299 · 2019: 241 · 2018: 278 · 2017: 267 · 2016: 283 · 2015: 283 · 2014: 302 · 2013: 296 · 2012: 302
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- U.S. Food and Drug Administration (FD-01462)
- National Institute of General Medical Sciences (GM 37188, R01GM037188)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- in vitro-in vivo correlation, drug dissolution, bioavailability, gastrointestinal permeability, oral drug absorption, solubility, transport modeling, dissolution profile, surfactants
- MeSH terms
- Biological Availability, Cimetidine, Pharmaceutical Preparations, Gastric Emptying, Jejunum, Mathematics, Models, Theoretical, Permeability, Piroxicam, Solubility, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.